Department of Health and Human Services January 11, 2012 – Federal Register Recent Federal Regulation Documents
Results 1 - 24 of 24
Agency Information Collection Activities: Fast Track Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery: IHS Web Site Customer Service Satisfaction Survey
As part of a Federal Government-wide effort to streamline the process to seek feedback from the public on service delivery, Indian Health Service has submitted a Generic Information Collection Request (Generic ICR): ``Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery'' to OMB for approval under the Paperwork Reduction Act (PRA) (44 U.S.C. 3501 et seq.).
National Toxicology Program (NTP) Final Process for Preparation of the Report on Carcinogens (RoC)
The NTP announces the final process for preparation of the RoC. The process is available on the NTP Web site (https:// ntp.niehs.nih.gov/go/rocprocess) or by contacting Dr. Ruth Lunn (see ADDRESSES).
Agency Information Collection Activities; Proposed Collection; Comment Request; State Annual Long-Term Care Ombudsman Report and Instructions for Older Americans Act Title VII
The Administration on Aging (AoA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection requirements relating to State Annual Long-Term Care Ombudsman Report and Instructions for Older Americans Act Title VII.
Determination That AVALIDE (Hydrochlorothiazide and Irbesartan), Oral Tablets, 25 Milligrams/300 Milligrams and 12.5 Milligrams/75 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) has determined that AVALIDE (hydrochlorothiazide and irbesartan), oral tablets, 25 milligrams (mg)/300 mg and 12.5 mg/75 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for hydrochlorothiazide and irbesartan, oral tablets, 25 mg/300 mg and 12.5 mg/75 mg, if all other legal and regulatory requirements are met.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
